Why should we screen for atrial fibrillation?

Atrial fibrillation (AF) constitutes an increasing challenge to the medical community and healthcare providers. With a prevalence of almost 3% in the adult Swedish population1 and a forecasted twofold or threefold increase by 2050 in the USA, we are facing a diagnosis with epidemic proportions. Apart from increased mortality, AF also increases the risk of heart failure, hospitalisations and ischaemic stroke.2 Of these complications, ischaemic stroke gives a particularly heavy burden on patients, their family and society. Ischaemic stroke is the most common reason for permanent neurological disability in the adult Western population, and stroke in connection to AF and cardiac emboli results in worse neurological outcome and higher mortality in relation to other subtypes of stroke.3 In patients with AF and stroke risk factors, oral anticoagulation (OAC) therapy reduces the risk of ischaemic stroke and systemic emboli by 60–70%. Unfortunately, there is...
Source: Heart - Category: Cardiology Authors: Tags: Press releases, Drugs: cardiovascular system, Epidemiology Editorials Source Type: research